The DEA’s New Cannabis Registration System May Matter More Than Legalization Headlines
The DEA’s new cannabis registration system may quietly reshape American cannabinoid medicine. This policy shift could influence research, taxation, institutional acceptance, and physician participation far beyond the headlines. Here is what clinicians…
What the 2026 DOJ Rescheduling Order Means in Practice
On April 23, 2026, the U.S. DOJ moved state-licensed medical cannabis to Schedule III, the first federal acknowledgment of accepted medical value in 55 years. Dr. Caplan breaks down what actually changed for patients, physicians, and the research…
‘A big step forward’: Medical marijuana reclassified as less dangerous, recreational growers …
The DEA’s decision to have medical marijuana reclassified marks a significant policy shift. Medical marijuana reclassified from Schedule I to Schedule III acknowledges its accepted medical use. This change may improve research and reduce regulatory…
State-Licensed Medical Marijuana Has Been Reclassified as a Less-Dangerous Drug …
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyResearchFederal RegulationMedical…
Cannabis Rescheduling Decision Appears Imminent, According to Reports – The Wild Hunt
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyFederal RegulationClinical…
Cannabis Rescheduling Could Happen Today. Don’t Call It Legalization. | High Times
Cannabis rescheduling news highlights a potential shift from Schedule I to Schedule III, impacting medical cannabis research and clinical practice. This change could reduce regulatory barriers and enable evidence-based treatment protocols. Patients and…
US System For Classifying Marijuana And Other Drugs Does ‘Immense Damage,’ Former DEA Official Says
The controlled substances act scheduling system critically affects marijuana research and patient access. Former DEA officials highlight how this system creates barriers to clinical practice. Understanding these impacts is essential for anticipating…
Regulatory Digest: DEA Enforcement & Controlled Substances March 2026
This regulatory digest covers DEA enforcement controlled substances updates relevant to cannabis and synthetic cannabinoid importation. The March 2026 notices highlight scheduling changes and import restrictions. Clinicians should stay informed about…